Austin Clinical Site
Austin, Texas, 78744, United States
NCT Number: NCT01489345
The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending multiple doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Austin, Texas, 78744, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
30 mg to 100 mg QD at a multiple dose, and 21 days duration
30 mg to 100 mg QD at a multiple dose, and 21 days duration
Time frame: 36 days
Time frame: 36 days
Ono Pharma USA Inc
Industry
A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06429137
Healthy
Biberach, Germany
View Trial DetailsNCT01520792
Healthy
Clermont-Ferrand, France
View Trial DetailsNCT07542886
Healthy
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial DetailsNCT02206178
Healthy
Clermont-Ferrand, France
View Trial Details